Dr. Heikki Lanckriet (PhD)
Dr. Heikki Lanckriet (PhD) (*1977, Belgium) holds a Bachelor’s and Master’s degree in Biochemical Engineering from the University of Ghent, Belgium and a PhD in Biochemical Engineering from the University of Cambridge, UK.
Dr. Lanckriet has over 20 years commercial & scientific experience in life sciences and has a track record of developing high growth technology businesses. Dr. Lanckriet has published scientific papers and is named inventor on a multitude of patents and has broad expertise and commercial experience in the life science area. He has a passion for science and innovation as well as strong commercial pragmatism. Dr. Lanckriet is currently the Chief Executive Officer of 4basebio PLC, Cambridge, United Kingdom, which is listed on the Alternative Investment Market (AIM) of the London Stock Exchange (LSE).
Dr. Lanckriet has been a member of the Supervisory Board of Epigenomics AG since June 2022. He is an independent member (within the meaning of the German Corporate Governance Code). Dr. Lanckriet’s current appointment ends in 2024.
He is also a member of the legally required Supervisory Board of Biofrontera AG, Leverkusen, Germany, and a member of comparable domestic and foreign control committees of the following commercial enterprises: 4basebio UK Ltd and 4basebio Discovery Limited, both Cambridge, United Kingdom; 4basebio SLU, Madrid, Spain; I2I Capital Limited, Cambridge, United Kingdom; KITHER BIOTECH S.R.L., Turin, Italy; and NeoPhore Ltd, Cambridge, United Kingdom.